ClariPi Inc. was founded in February 2015 to provide innovative solutions for the unmet needs in medical imaging fields through the convergence of intelligent big data computing and medical imaging technologies. Our products were born through a long-term collaborative research between engineering and medical experts. Our products were designed to help medical imaging experts make confident decisions and clearer information with convenient decision guidance. We are providing innovative solutions to help medical experts cope with the rapidly changing landscape of 21st century healthcare services.
Jong Hyo, Kim
CO-CEO & CTO
Holds concurrent position as a professor at the Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University.
ClariCT.AI is an innovative vendor-neutral CT denoising solution based on Deep Learning technology. ClariCT.Al’s unique Deep-learned Clarity Engine clears CT noise, and turns an existing CT into a novel AI-empowered CT using only DICOM standard. ClariCT.AI provides multiple Deep Learning Models pertained with millions of images for different organs at varying noise levels from most existing scanner models, which is able to distinguish anatomical structures from thousands of different noise patterns and to serve noise-clean high-quality images. Because of the powerful denoising performance, when using ultra-low-dose, ClariCT.AI offers image quality comparable to high-dose CT images. ClariCT.AI removes strong noise and artifacts without suffering distortion and plastic appearance.
Hyun Sook, Park
We specialize in medical imaging diagnostic solutions based on artificial intelligence. The best experts in the field gathered to develop various medical imaging diagnostic solutions by integrating artificial intelligence image processing and big data technology. ClariCT.AI, our flagship product, is an ultra-low-dose CT image denoising solution created through deep learning based on high-quality big data.
In addition, we are developing various diagnostic solutions for emphysema, breast density, abdominal metabolic syndrome, and liver fat by using artificial intelligence CT image processing technology. All employees of ClariPi will do their best to continuously provide innovative artificial intelligence medical imaging solutions that contribute to and “for the health and happiness of mankind”.
ClariSigmam acquired FDA clearance and CE certification
Additional patents applied and registered
The K-Innovation Company Award (Oct. 27, 2021)
Won the grand prize in the Medical Imaging AI Challenge hosted by the Korea Institute of Industrial Technology (KTL) (Apr. 22, 2021)
Selected as a Good Invention Priority purchase recommendation company by Korea Invention Promotion Association (2020.11.13)
What Our Clients Say
“Recent years have seen stronger regulations for lowering radiation doses of CT scans in the routine practice, which made it troublesome for radiologists to decide the best balance between the low-dose principle and diagnostic image quality. ClariCT.AI, an artificial intelligence product, has made it possible to meet both goals without having to worry about this every day. It was encouraging to see that even though the CT scans were taken with the dose significantly lowered to less than 1/4 compared to the previous ones, it was possible to obtain an image that had the same image quality as or even better than that of the normal dose, making confident image readings possible. My team already published a couple of papers using ClariCT.AI technique, and more clinical studies are underway to explore its potential in different specialty areas. I confidently recommend using ClariCT.AI in low-dose CT imaging practices.”
Dr. Ahmed Othman
Tubingen University Consultant Radiologist, PD
“Hearing reports from radiologists and radiographers in my hospital as well as in other hospitals in Korea regarding ClariCT.AI, the advantage of this software is its compatibility with any brand of CT equipment. Automatic image denoising and data transfer are possible without any manipulation after initial setup, the program is simple to use, the range of application for the human body is wide, the initial noise level setup provides an innovative noise reduction, and it is possible to produce optimal images with small dose. I hope that the ClariCT.AI software will be actively utilized in my home country and abroad to reduce radiation harm to people around the world.”
Prof. Byungin Choi
Chung-Ang University Hospital Clinical Chair Professor
“As a result of using ClariCT.AI to reduce about 40 – 50% of the general low-dose lung CT dose, the quality of the image was much improved, and it was helpful in the detection of nodules as well as the analysis of inflammatory lesions. Even if it (CT scan) is performed due to respiratory symptoms such as coughing, after the first examination with ultra-low-dose CT using ClariCT.AI, contrast agent is used only when necessary, and there is no difficulty in diagnosing lesions. It is helpful in diagnosing various respiratory diseases as more respiratory patients undergo CT scans with increased awareness from clinicians as well as patients regarding the better health safety with ultra-low-dose radiation. We hope that in the future, it (ClarICT.AI) will become an alternative to simple radiographic examination.”
Dr. Dong-geun Yoo
CEO at Leaders Internal Medicine Radiology
ClariPi will be at SIIM this year!
Jul 13, 2022 - Jul 17, 2022
ClariPi will be at SIIM (booth #601) from July 13-17, 2022 at Gaylord Palms Resort & Convention Center, Florida. If you are interested in our products, you could visit our booth or arrange a demo session online. Just message us to schedule a meeting! Thank you!
ClariPi teams up with Nuance to showcase the ClariCT.AI in their Nuance AI Marketplace, which connects more than 9,000 facilities in the U.S. With the new cloud-based feature, the ClariCT.AI is now even more easily and readily accessible than ever before.